KLF6 degradation after apoptotic DNA damage

FEBS Letters

Volumn 580, Issue 30, 2006, Pages 6981-6986

  Banck, Michaela S ^a   Beaven, Simon W ^a   Narla, Goutham ^a   Walsh, Martin J ^a   Friedman, Scott L ^a   Beutler, Andreas S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer cells; Carcinogenesis; Chemosensitivity; DNA damage; KLF6; Kr ppel like factor; Proteasomal degradation; Ubiquitin

Indexed keywords

CISPLATIN; DNA; DOXORUBICIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GENETICS; CELL LINE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ULTRAVIOLET B RADIATION;

ANIMALS; APOPTOSIS; CELL LINE; CISPLATIN; DNA DAMAGE; HALF-LIFE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 33845454853     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.10.077     Document Type: Article

References (26)

1. Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., Martignetti J.A., and Friedman S.L. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294 (2001) 2563-2566
2. Reeves H.L., Narla G., Ogunbiyi O., Haq A.I., Katz A., Benzeno S., Hod E., Harpaz N., Goldberg S., Tal-Kremer S., Eng F.J., Arthur M.J., Martignetti J.A., and Friedman S.L. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126 (2004) 1090-1103
3. Kremer-Tal S., Reeves H.L., Narla G., Thung S.N., Schwartz M., Difeo A., Katz A., Bruix J., Bioulac-Sage P., Martignetti J.A., and Friedman S.L. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40 (2004) 1047-1052
4. Cho Y.G., Kim C.J., Park C.H., Yang Y.M., Kim S.Y., Nam S.W., Lee S.H., Yoo N.J., Lee J.Y., and Park W.S. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24 (2005) 4588-4590
5. Li D., Yea S., Li S., Chen Z., Narla G., Banck M., Laborda J., Tan S., Friedman J.M., Friedman S.L., and Walsh M.J. KLF6 promotes preadipocyte differentiation through histone deacetylase 3 (HDAC3)-dependent repression of Dlk1. J. Biol. Chem. 280 (2005) 26941-26952
6. Wang S., Chen X., Zhang W., and Qiu F. KLF6mRNA expression in primary hepatocellular carcinoma. J. Huazhong Univ. Sci. Technol. Med. Sci. 24 (2004) 585-587
7. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., Thomas D.G., Lizyness M.L., Kuick R., Hayasaka S., Taylor J.M., Iannettoni M.D., Orringer M.B., and Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8 (2002) 816-824
8. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M., and Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin. Invest. 113 (2004) 913-923
9. Narla G., Difeo A., Reeves H.L., Schaid D.J., Hirshfeld J., Hod E., Katz A., Isaacs W.B., Hebbring S., Komiya A., McDonnell S.K., Wiley K.E., Jacobsen S.J., Isaacs S.D., Walsh P.C., Zheng S.L., Chang B.L., Friedrichsen D.M., Stanford J.L., Ostrander E.A., Chinnaiyan A.M., Rubin M.A., Xu J., Thibodeau S.N., Friedman S.L., and Martignetti J.A. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65 (2005) 1213-1222
10. Benzeno S., Narla G., Allina J., Cheng G.Z., Reeves H.L., Banck M.S., Odin J.A., Diehl J.A., Germain D., and Friedman S.L. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 64 (2004) 3885-3891
11. Slavin D.A., Koritschoner N.P., Prieto C.C., Lopez-Diaz F.J., Chatton B., and Bocco J.L. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene 23 (2004) 8196-8205
12. Kaczynski J., Cook T., and Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol. 4 (2003) 206
13. Quadrini K.J., and Bieker J.J. EKLF/KLF1 is ubiquitinated in vivo and its stability is regulated by activation domain sequences through the 26S proteasome. FEBS Lett. 580 (2006) 2285-2293
14. Zhang X., Srinivasan S.V., and Lingrel J.B. WWP1-dependent ubiquitination and degradation of the lung Kruppel-like factor, KLF2. Biochem. Biophys. Res. Commun. 316 (2004) 139-148
15. Chen C., Sun X., Guo P., Dong X.Y., Sethi P., Cheng X., Zhou J., Ling J., Simons J.W., Lingrel J.B., and Dong J.T. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J. Biol. Chem. 280 (2005) 41553-41561
16. Chen Z.Y., Wang X., Zhou Y., Offner G., and Tseng C.C. Destabilization of Kruppel-like factor 4 protein in response to serum stimulation involves the ubiquitin-proteasome pathway. Cancer Res. 65 (2005) 10394-10400
17. Lin X., Ramamurthi K., Mishima M., Kondo A., Christen R.D., and Howell S.B. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res. 61 (2001) 1508-1516
18. Hata T., Yamamoto H., Ngan C.Y., Koi M., Takagi A., Damdinsuren B., Yasui M., Fujie Y., Matsuzaki T., Hemmi H., Xu X., Kitani K., Seki Y., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., and Monden M. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol. Cancer Ther. 4 (2005) 1585-1594
19. Shiraki K., Yamanaka T., Inoue H., Kawakita T., Enokimura N., Okano H., Sugimoto K., Murata K., and Nakano T. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int. J. Oncol. 26 (2005) 1273-1281
20. Hermisson M., and Weller M. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells. Cell Death Differ. 10 (2003) 1078-1089
21. Lee D.H., and Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8 (1998) 397-403
22. Pickart C.M., and Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695 (2004) 55-72
23. Bernstein C., Bernstein H., Payne C.M., and Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 511 (2002) 145-178
24. Ivana Scovassi A., and Diederich M. Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem. Pharmacol. 68 (2004) 1041-1047
25. Fukazawa T., Fujiwara T., Uno F., Teraishi F., Kadowaki Y., Itoshima T., Takata Y., Kagawa S., Roth J.A., Tschopp J., and Tanaka N. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20 (2001) 5225-5231
26. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., and Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66 (2006) 2815-2825